Another notch for imiquimod?

New Orleans - Topical imiquimod (Aldara) treatment may play a role in preventing UVB-induced cutaneous immunosuppression, Anthony A. Gaspari, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content

Establishing a Culture of Respect: Responding to Patient-Initiated Harassment

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

New Advancements in Surgical Scar Revision

March 19th 2023

Establishing a Culture of Respect: Responding to Patient-Initiated Harassment

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

New Advancements in Surgical Scar Revision

March 19th 2023

Establishing a Culture of Respect: Responding to Patient-Initiated Harassment

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

New Advancements in Surgical Scar Revision

March 19th 2023
© 2023 MJH Life Sciences

All rights reserved.